Cyclic bridged analogs of isoCA-4: Design, synthesis and biological evaluation - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue European Journal of Medicinal Chemistry Année : 2021

Cyclic bridged analogs of isoCA-4: Design, synthesis and biological evaluation

Jérome Bignon
Francois Saller
Delphine Borgel
Mouad Alami

Résumé

In this work, a series of cyclic bridged analogs of isocombretastatin A-4 (isoCA-4) with phenyl or pyridine linkers were designed and synthesized. The synthesis of the desired analogs was performed by the formation of nitro-vinyl intermediates, followed by a Cadogan cyclization. Structure activity relationship (SAR) study demonstrates the critical role of the combination of quinaldine as ring A, pyridine as the linker, and indole as ring B in the same molecule, for the cytotoxic activity. Among all tested compounds, compound 42 showed the highest antiproliferative activity against a panel of cancer cell lines with average IC50 values of 5.6 nM. Also, compound 42 showed high antiproliferative activity against the MDR1-overexpressing K562R cell line; thus, it was 1.5-and 12-fold more active than the reference compounds, isoCA-4 and CA-4, respectively. Moreover, 42 displayed a strong antiproliferative activity against the colon-carcinoma cells (HT-29), which are resistant to combretastatin A-4 and isoCA-4, and it was found to be 8000-fold more active than natural CA-4. Compound 42 also effectively inhibited tubulin polymerization both in vitro and in cells, and induced cell cycle arrest in G2/M phase. Next, we demonstrated that compound 42 dose-dependently caused caspase-induced apoptosis of K562 cells through mitochondrial dysfunction. Finally, we evaluated the effect of compound 42 in human no cancer cells compared to the reference compound. We demonstrated that 42 was 73 times less cytotoxic than isoCA-4 in quiescent peripheral blood lymphocytes (PBLs). In summary, these results suggest that compound 42 represents a promising tubulin inhibitor worthy of further investigation.
Fichier principal
Vignette du fichier
Manuscript Word VF.pdf (1.79 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03034493 , version 1 (04-01-2021)

Identifiants

Citer

Shannon Pecnard, Olivier Provot, Hélène Levaique, Jérome Bignon, Laurie Askenatzis, et al.. Cyclic bridged analogs of isoCA-4: Design, synthesis and biological evaluation. European Journal of Medicinal Chemistry, 2021, 209, pp.112873. ⟨10.1016/j.ejmech.2020.112873⟩. ⟨hal-03034493⟩
110 Consultations
158 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More